Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study
VANCOUVER, BC — (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to… Read More



